Brain Tumour Drug Approved for NHS Scotland Following Campaign by Patients

Brain tumour drug approved for NHS Scotland following campaign by patients

A drug which can slow the growth of brain tumours has been approved for use on NHS Scotland, following a campaign by those affected

Scots student welcomes decision to approve new brain tumour treatment

The treatment will be used for people aged 12 or older with IDH-mutated low-grade gliomas

Vorasidenib approved in Scotland – people living with grade 2 brain tumours in England must not be left behind.

Scotland’s medicines regulator has approved the first targeted therapy for low grade brain tumours in a generation. brainstrust calls on England to address the inequity of access to Vorasidenib. Scotland’s medicines regulator has approved the first targeted therapy for low grade brain tumours in a generation. brainstrust calls on England to address the inequity of access to Vorasidenib. The Scottish Medicines Consortium (SMC) today confirmed tha…

Vorasidenib approved for use in Scotland

Today, the Scottish Medicines Consortium (SMC) have approved vorasidenib – also known by its brand name Voranigo – to be used by NHS Scotland to treat people aged 12 or older with IDH-mutated, low grade gliomas – including astrocytomas and ogliodendrogliomas.   We wholeheartedly welcome this news as it’s the first targeted drug to be approved to treat these tumours and only the second new drug to be approved to treat brain tumours since temozolo…